| Field | Specification |
|---|---|
| Target | |
| Alternative names | Breast cancer anti-estrogen resistance protein 3;Novel SH2-containing protein 2;SH2 domain-containing protein 3B;BCAR3;NSP2, SH2D3B;UNQ271/PRO308; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human BCAR3, different from the related mouse sequence by five amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes breast cancer anti-estrogen resistance protein 3 (gene BCAR3) in human, mouse and rat samples and is validated for IHC and Western blot. The predicted molecular weight is 92.6 kDa, and the supplier reports an observed band at about 93 kDa.
BCAR3 is an adaptor protein with an SH2 domain and a GEF-like domain that binds p130Cas (BCAR1) and works downstream of growth factor receptors. It promotes cell proliferation, migration and actin reorganization, and it was identified, like BCAR1, through its ability to confer antiestrogen resistance in breast cancer cells.
| Target | Breast cancer anti-estrogen resistance protein 3 (gene BCAR3; UniProt O75815, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 92.6 kDa |
| Observed MW | 93 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| IHC (paraffin sections) | 0.5–1 µg/mL (Human, Mouse, Rat) |
|---|---|
| Western blot | 0.1–0.5 µg/mL (Human) |
Samples with a confirmed band (WB): HepG2 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): mouse lymphaden tissue, rat spleen tissue, human tonsil tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide from the C-terminal region of human BCAR3. It differs from the mouse sequence at five residues.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places breast cancer anti-estrogen resistance protein 3 in the cytoplasm and cell junction. Tissue expression noted by UniProt (human): Ubiquitously expressed. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Chenxi Zeng et al. (2024) Localized Administration of Bcar3 siRNA via Nano-Self-Assembly to Treat Idiopathic Pulmonary Fibrosis by Disrupting Macrophage-Fibroblast Crosstalk. International Journal of Nanomedicine. 10.2147/IJN.S444470
